文献速递心律失常

房颤合并肾功能不全患者的非维生素K拮抗剂口服抗凝药剂量模式与结局

Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

基于美国大型行政数据库纳入2010年10月1日至2015年9月30日启动阿哌沙班、达比加群或利伐沙班的14,865例房颤患者,分析NOAC剂量与说明书不一致的处方模式及其与卒中和大出血的关联。有减量指征者43.0%可能过度给药,与大出血风险升高相关;无减量指征者13.3%可能给药不足,在阿哌沙班患者中与卒中风险升高相关。

要点

  • 有肾脏减量指征却用标准剂量与大出血风险升高相关,卒中无显著差异。
  • 无肾脏减量指征却用减量方案在阿哌沙班患者中与卒中风险升高相关。
  • 常规实践中NOAC剂量常与药品标签不一致,需按肾功能核对剂量。

核心结论

  • 常规临床实践中NOAC处方剂量常与药品标签不一致。
  • 严重肾功能不全患者过度给药可能损害安全性而无有效性获益。
  • 阿哌沙班治疗且肾功能正常或轻度损害患者给药不足可能损害有效性而无安全性获益。

研究设计与样本

  • 利用美国大型行政数据库识别2010年10月1日至2015年9月30日启动阿哌沙班、达比加群或利伐沙班的14,865例房颤患者。
  • 分析有肾脏减量指征者使用标准剂量(潜在过度给药)及无肾脏减量指征者使用减量剂量(潜在给药不足)的情况。
  • 在倾向评分匹配队列中采用Cox比例风险回归分析结局。

主要发现

  • 1,473例有肾脏减量指征患者中43.0%可能过度给药,与大出血风险升高相关(HR 2.19;95%CI 1.07至4.46),三种NOAC合并分析卒中无统计学显著差异。
  • 13,392例无肾脏减量指征患者中13.3%可能给药不足,在阿哌沙班治疗患者中与卒中风险升高相关(HR 4.87;95%CI 1.30至18.26),大出血无统计学显著差异。
  • 无肾脏减量指征的达比加群或利伐沙班治疗患者中未见统计学显著关联。

关键数值与推荐

  • 有肾脏减量指征者潜在过度给药比例43.0%,与大出血相关HR 2.19(95%CI 1.07至4.46)。
  • 无肾脏减量指征者潜在给药不足比例13.3%,阿哌沙班组卒中相关HR 4.87(95%CI 1.30至18.26)。

临床怎么用

  • 处方NOAC前应依据肾功能及药品标签核对该减量还是标准剂量,避免过度或不足给药。
  • 对严重肾功能不全患者尤需避免未减量使用;对阿哌沙班肾功能正常或轻度损害患者尤需避免无指征减量。

局限性

  • 为行政数据库分析,可能存在处方与临床信息不完整及混杂。
  • 三种NOAC合并分析卒中结果,达比加群和利伐沙班无肾脏减量指征亚组未见显著关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dose reduction of non-vitamin K antagonist oral anticoagulants (NOACs) is indicated in patients with atrial fibrillation (AF) with renal impairment. Failure to reduce the dose in patients with severe kidney disease may increase bleeding risk, whereas dose reductions without a firm indication may decrease the effectiveness of stroke prevention. OBJECTIVES: The goal of this study was to investigate NOAC dosing patterns and associated outcomes, i.e., stroke (ischemic stroke and systemic embolism) and major bleeding in patients treated in routine clinical practice. METHODS: Using a large U.S. administrative database, 14,865 patients with AF were identified who initiated apixaban, dabigatran, or rivaroxaban between October 1, 2010, and September 30, 2015. We examined use of a standard dose in patients with a renal indication for dose reduction (potential overdosing) and use of a reduced dose when the renal indication is not present (potential underdosing). Cox proportional hazards regression was performed in propensity score-matched cohorts to investigate the outcomes. RESULTS: Among the 1,473 patients with a renal indication for dose reduction, 43.0% were potentially overdosed, which was associated with a higher risk of major bleeding (hazard ratio: 2.19; 95% confidence interval: 1.07 to 4.46) but no statistically significant difference in stroke (3 NOACs pooled). Among the 13,392 patients with no renal indication for dose reduction, 13.3% were potentially underdosed. This underdosing was associated with a higher risk of stroke (hazard ratio: 4.87; 95% confidence interval: 1.30 to 18.26) but no statistically significant difference in major bleeding in apixaban-treated patients. There were no statistically significant relationships in dabigatran- or rivaroxaban-treated patients without a renal indication. CONCLUSIONS: In routine clinical practice, prescribed NOAC doses are often inconsistent with drug labeling. These prescribing patterns may be associated with worse safety with no benefit in effectiveness in patients with severe kidney disease and worse effectiveness with no benefit in safety in apixaban-treated patients with normal or mildly impaired renal function.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Yao X, Shah ND, Sangaralingham LR, et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol. 2017. PMID: 28595692. doi:10.1016/j.jacc.2017.03.600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。